Author

Simone Critchlow

Observed names: Critchlow, Simone, S Critchlow, S. Critchlow

Observed institution: BresMed

ORCID: 0000-0001-6862-765X

Observed ORCID: 0000-0001-6862-765X

OpenAlex ID: A5080101180

Costing the COVID-19 Pandemic: An Exploratory Economic Evaluation of Hypothetical Suppression Policy in the United Kingdom

2020 · Darshan Zala, Iris Mosweu, et al. · Value in Health · 40

PDF

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

2021 · Jaesh Naik, Laura Puzniak, et al. · Infectious Diseases and Therapy · 12

PDF

A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future

2016 · Simone Critchlow, Matthew Hirst, et al. · Journal of Medical Economics · 9

PDF

Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland

2023 · Simone Critchlow, Ash Bullement, et al. · Future Oncology · 8

HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals

2023 · R. Batteson, S. Critchlow, et al. · Value in Health · 2

Estimating the Relative Treatment Effect and Corresponding Cost-Effectiveness Estimates of Inotuzumab Ozogamicin Vs. Blinatumomab for Adults with Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukaemia (B-ALL) in the United Kingdom (UK)

2019 · Simone Critchlow, Miranda Cooper, et al. · Blood · 2

HTA225 A Review of External Evidence Used to Support Survival Extrapolation in Assessments of Cancer Drugs by the National Institute for Health and Care Excellence (NICE)

2022 · A Bullement, S Critchlow, et al. · Value in Health · 1

POSC4 Modeling Health-Related Outcomes With Avelumab as a First-Line Maintenance Treatment Following Chemotherapy vs. Best Supportive Care (BSC) for Patients With Locally Advanced or Metastatic Urothelial Cancer in the UK

2022 · S Critchlow, Y Xiao, et al. · Value in Health · 1

An Exploration of Techniques for Addressing Uncertainty in Survival Estimates used Within Partitioned-Survival Models

2016 · A Bullement, S Critchlow · Value in Health · 1

PDF

HTA143 Examining the Relationship Between the NICE WTP Threshold and the Severity Modifier

2025 · Simone Critchlow, Cameron Lilley, et al. · Value in Health

HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions

2025 · David Aitken, Simone Critchlow, et al. · Value in Health

HTA6 A Decade in Decision Making: Reviewing Trends in STAS by NICE in Different Disease Areas

2025 · Rachael Batteson, Simone Critchlow · Value in Health

HTA319 A 10-Year Review of the Willingness-to-Pay (WTP) Thresholds for Single Technology Appraisals From the National Institute for Health and Care Excellence (NICE)

2024 · S Critchlow, C Lilley · Value in Health

PDF

150 (PB138): AZD3470 induces regressions and durable responses in MTAPdeficient tumor models of diverse tumor indications

2024 · J. Urosevic, L. Magiera, et al. · European Journal of Cancer

HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of Probabilistic Sensitivity Analysis (PSA): A Case Study

2023 · S. Critchlow, T. Douglas, et al. · Value in Health

PDF

Pcn380 a Targeted Review Evaluating Uncertainty in Single Technology Appraisal Submissions for Treatments Approved for Use Since the Introduction of the 'new' Cancer Drugs Fund

2019 · S. Critchlow, C. Lilley, et al. · Value in Health

PDF

2200. Cost-effectiveness of Ceftolozane/Tazobactam for Treating Ventilated Nosocomial Bacterial Pneumonia

2019 · Jaesh Naik, Joe Yang, et al. · Open Forum Infectious Diseases

PDF

Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin Versus Investigators Choice (IC) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia (R/R B-ALL)

2017 · R Batteson, S Critchlow, et al. · Value in Health

Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma

2016 · S Critchlow, D Lee, et al. · Value in Health

Cost-Effectiveness Modelling for Neuropathic Pain Treatments: An Exploration to Identify Comparative Importance of Model Parameters

2015 · S Critchlow, M Hirst, et al. · Value in Health

PDF

Works count: 22

Citation count: 76

H-index: 4

I10-index: 2